Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study

References

1. 1.↵
   Central Brain Tumor Registry of the United States. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. 2011. http://www.cbtrus.org. Accessed 2011 Feb 21.
2. 2.↵
   1. Gutin PH,
   2. Iwamoto FM,
   3. Beal K,
   4. et al

   . Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;26:156–63. Epub 2009 Jan 23
3. 3.↵
   1. Reardon DA,
   2. Fink KL,
   3. Mikkelsen T,
   4. et al

   . Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610–17. Epub 2008 Nov 3

   Abstract/FREE Full Text
4. 4.↵
   1. Vredenburgh JJ,
   2. Desjardins A,
   3. Herndon JE 2nd.,
   4. et al

   . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007:13;1253–59

   Abstract/FREE Full Text
5. 5.↵
   1. Fiveash JB,
   2. Spencer SA

   . Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J 2003;9:222–29

   CrossRefPubMed
6. 6.↵
   1. Stupp R,
   2. Mason WP,
   3. van den Bent MJ,
   4. et al

   . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Kumar AJ,
   2. Leeds NE,
   3. Fuller GN,
   4. et al

   . Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377–84

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Wen PY,
   2. Macdonald DR,
   3. Reardon DA,
   4. et al

   . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72. Epub 2010 Mar 15

   Abstract/FREE Full Text
9. 9.↵
   1. Aronen HJ,
   2. Gazit IE,
   3. Louis DN,
   4. et al

   . Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Aronen HJ,
    2. Glass J,
    3. Pardo FS,
    4. et al

    . Echo-planar MR cerebral blood volume mapping of gliomas: clinical utility. Acta Radiol 1995;36:520–28

    PubMed
11. 11.↵
    1. Aronen HJ,
    2. Perkio J

    Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am 2002;12:501–23

    CrossRefPubMed
12. 12.↵
    1. Barajas RF Jr.,
    2. Hodgson JG,
    3. Chang JS,
    4. et al

    . Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology 2010;254:564–76

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Bisdas S,
    2. Kirkpatrick M,
    3. Giglio P,
    4. et al

    . Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 2009;30:681–88. Epub 2009 Jan 29

    Abstract/FREE Full Text
14. 14.↵
    1. Cha S

    . Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006;27:475–87

    FREE Full Text
15. 15.↵
    1. Cha S,
    2. Knopp EA,
    3. Johnson G,
    4. et al

    . Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Covarrubias DJ,
    2. Rosen BR,
    3. Lev MH

    . Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004;9:528–37

    Abstract/FREE Full Text
17. 17.↵
    1. Deibler AR,
    2. Pollock JM,
    3. Kraft RA,
    4. et al

    . Arterial spin-labeling in routine clinical practice. Part 3. Hyperperfusion patterns. AJNR Am J Neuroradiol 2008;29:1428–35. Epub 2008 Mar 20

    Abstract/FREE Full Text
18. 18.↵
    1. Jackson A,
    2. Kassner A,
    3. Annesley-Williams D,
    4. et al

    . Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. AJNR Am J Neuroradiol 2002;23:7–14

    Abstract/FREE Full Text
19. 19.↵
    1. Kim HS,
    2. Kim SY

    . A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007;28:1693–99. Epub 2007 Sep 20

    Abstract/FREE Full Text
20. 20.↵
    1. Kim MJ,
    2. Kim HS,
    3. Kim JH,
    4. et al

    . Diagnostic accuracy and interobserver variability of pulsed arterial spin labeling for glioma grading. Acta Radiol 2008;49:450–57

    FREE Full Text
21. 21.↵
    1. Knopp EA,
    2. Cha S,
    3. Johnson G,
    4. et al

    . Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–98

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Law M,
    2. Oh S,
    3. Babb JS,
    4. et al

    . Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 2006;238:658–67. Epub 2006 Jan 5

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Law M,
    2. Oh S,
    3. Johnson G,
    4. et al

    . Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099–107

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Law M,
    2. Yang S,
    3. Babb JS,
    4. et al

    . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55

    Abstract/FREE Full Text
25. 25.↵
    1. Law M,
    2. Yang S,
    3. Wang H,
    4. et al

    . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

    Abstract/FREE Full Text
26. 26.↵
    1. Law M,
    2. Young RJ,
    3. Babb JS,
    4. et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98. Epub 2008 Mar 18

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Lev MH,
    2. Ozsunar Y,
    3. Henson JW,
    4. et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
28. 28.↵
    1. Lev MH,
    2. Rosen BR

    . Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999;9:309–31

    PubMedWeb of Science
29. 29.↵
    1. Shin JH,
    2. Lee HK,
    3. Kwun BD,
    4. et al

    . Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. AJR Am J Roentgenol 2002;179:783–89

    CrossRefPubMed
30. 30.↵
    1. Warmuth C,
    2. Gunther M,
    3. Zimmer C

    . Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523–32. Epub 2003 Jun 20

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Barajas RF Jr.,
    2. Chang JS,
    3. Segal MR,
    4. et al

    . Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486–96. Epub 2009 Sep 29

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Hu LS,
    2. Baxter LC,
    3. Smith KA,
    4. et al

    . Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552–58. Epub 2008 Dec 4

    Abstract/FREE Full Text
33. 33.↵
    1. Sugahara T,
    2. Korogi Y,
    3. Tomiguchi S,
    4. et al

    . Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901–09

    Abstract/FREE Full Text
34. 34.↵
    1. Hollingworth W,
    2. Jarvik JG

    . Technology assessment in radiology: putting the evidence in evidence-based radiology. Radiology 2007;244:31–38. Epub 2007 May 23

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Deibler AR,
    2. Pollock JM,
    3. Kraft RA,
    4. et al

    . Arterial spin-labeling in routine clinical practice. Part 1. Technique and artifacts. AJNR Am J Neuroradiol 2008;29:1228–34. Epub 2008 Mar 27

    Abstract/FREE Full Text
36. 36.↵
    1. Luh WM,
    2. Wong EC,
    3. Bandettini PA,
    4. et al

    . QUIPSS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magn Reson Med 1999;41:1246–54

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Kim SG,
    2. Tsekos NV

    . Perfusion imaging by a flow-sensitive alternating inversion recovery (FAIR) technique: application to functional brain imaging. Magn Reson Med 1997;37:425–35

    PubMedWeb of Science
38. 38.↵
    1. Kim SG,
    2. Tsekos NV,
    3. Ashe J

    . Multi-slice perfusion-based functional MRI using the FAIR technique: comparison of CBF and BOLD effects. NMR Biomed 1997;10:191–96

    CrossRefPubMed
39. 39.↵
    1. Kong DS,
    2. Kim ST,
    3. Kim EH,
    4. et al

    . Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–87. Epub 2011 Jan 20

    Abstract/FREE Full Text
40. 40.↵
    1. Jain R,
    2. Gutierrez J,
    3. Narang J,
    4. et al

    . In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 2011;32:388–94. Epub 2010 Nov 11

    Abstract/FREE Full Text
41. 41.↵
    1. Nabors LB,
    2. Mikkelsen T,
    3. Rosenfeld SS,
    4. et al

    . Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651–57

    Abstract/FREE Full Text
42. 42.↵
    1. Price SJ,
    2. Green HA,
    3. Dean AF,
    4. et al

    . Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas: an image-guided biopsy study. AJNR Am J Neuroradiol 2011;32:501–06. Epub 2010 Dec 16

    Abstract/FREE Full Text
43. 43.↵
    1. Ozsunar Y,
    2. Mullins ME,
    3. Kwong K,
    4. et al

    . Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 2010;17:282–90. Epub 2010 Jan 12

    CrossRefPubMed
44. 44.↵
    1. Johnson AJ,
    2. Ying J,
    3. El Gammal T,
    4. et al

    . Which MR imaging sequences are necessary in determining the need for radiation therapy for cord compression? A prospective study. AJNR Am J Neuroradiol 2007;28:32–37

    Abstract/FREE Full Text
45. 45.↵
    1. Yin Y,
    2. Evanoff BA,
    3. Gilula LA,
    4. et al

    . Surgeons' decision making in patients with chronic wrist pain: role of bilateral three-compartment wrist arthrography—prospective study. Radiology 1996;200:829–32

    PubMed